Coagulation testing is a common practice used for patients under oral anticoagulation therapy as well as those undergoing cardiac surgeries including cardiopulmonary bypass surgery. The early monitoring of anticoagulants during or before surgery is crucial as it enables surgeons and physicians to control the level of bleeding.
New analysis from Frost & Sullivan (drugdiscovery.frost.com), European Coagulation Testing Market, finds that the market earned revenues of around $500.0 million in 2006 and estimates this to reach approximately $850 million in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the European Coagulation Testing Market, send an email to Radhika Menon Theodore, Corporate Communications at rmtheodore[.]frost.com with your full name, company name, title, telephone number, email address, city, state, and country. We will send you the information through email upon receipt of the above information.
“In Europe, coagulation monitoring is moving towards point-of-care (POC) testing, which ensures quick generation of results and better patient care,” notes Frost & Sullivan Research Analyst Gayathry Ramachandran. “POC coagulation tests have made life simpler, as they enable patients to be well informed about the disease state, thus boosting patient confidence and reducing hospital visits.”
With the increase in the number of patients under anticoagulant therapy, it is very important to closely monitor the prothrombin time (PT) and the international standardised ratio (INR). This is being achieved by installing POC instruments in emergency units, outpatient wards as well as patient homes to enable self-testing. This reduces the burden on hospitals as well as physician offices and prevents the drastic effects of anticoagulants and other bleeding disorders.
Clearly, the growth of POC is generated by quick turn-around-times (TAT) and easy-to-use technology. At the same time, laboratory tests continue to be preferred in some European countries since they are cost effective and well reimbursed when compared to POC tests.
Presently, laboratory tests generate delayed results and do not support fast treatment processes. Hence, there is a need to produce timely results that will result in improved patient care. With an increasing number of tests moving towards POC, the volume of tests in laboratories is adversely affected. To overcome this challenge, laboratories are slowly adopting high-volume analyzers to perform special coagulation tests, which have not yet reached the POC market.
“The laboratory testing arena is facing challenges related to the lack of qualified lab personnel,” explains Ms. Ramachandran. “Tests conducted in the laboratories by non-laboratory personnel are giving rise to inappropriate quality control.”
In this situation, it is crucial to maintain international quality in the results of laboratory and POC tests. The most effective strategy is to conduct training programmes for laboratory and non-laboratory personnel to maintain the high quality of results. This should include instrument handling and patient preparation, among others.
European Coagulation Testing Market is part of the Drug Discovery Technologies Growth Partnership Service, which also includes research on the European molecular diagnostics markets as well as the IVD market, the cancer diagnostics market and the primary care diagnostics markets in the region. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics.